These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. Cho L; Marso SP; Bhatt DL; Topol EJ J Womens Health Gend Based Med; 2000 Sep; 9(7):741-6. PubMed ID: 11025866 [TBL] [Abstract][Full Text] [Related]
5. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. EPISTENT Investigators Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272 [TBL] [Abstract][Full Text] [Related]
6. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Brener SJ; Barr LA; Burchenal JE; Katz S; George BS; Jones AA; Cohen ED; Gainey PC; White HJ; Cheek HB; Moses JW; Moliterno DJ; Effron MB; Topol EJ Circulation; 1998 Aug; 98(8):734-41. PubMed ID: 9727542 [TBL] [Abstract][Full Text] [Related]
7. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997 [TBL] [Abstract][Full Text] [Related]
8. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). Islam MA; Blankenship JC; Balog C; Iliadis EA; Lincoff AM; Tcheng JE; Califf RM; Topol EJ; Am J Cardiol; 2002 Nov; 90(9):916-21. PubMed ID: 12398954 [TBL] [Abstract][Full Text] [Related]
9. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Roffi M; Moliterno DJ; Meier B; Powers ER; Grines CL; DiBattiste PM; Herrmann HC; Bertrand M; Harris KE; Demopoulos LA; Topol EJ; Circulation; 2002 Jun; 105(23):2730-6. PubMed ID: 12057986 [TBL] [Abstract][Full Text] [Related]
10. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW; Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213 [TBL] [Abstract][Full Text] [Related]
11. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. Cho L; Topol EJ; Balog C; Foody JM; Booth JE; Cabot C; Kleiman NS; Tcheng JE; Califf R; Lincoff AM J Am Coll Cardiol; 2000 Aug; 36(2):381-6. PubMed ID: 10933346 [TBL] [Abstract][Full Text] [Related]
12. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization. Ibbotson T; McGavin JK; Goa KL Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074 [TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A; Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766 [TBL] [Abstract][Full Text] [Related]
14. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. Valgimigli M; Percoco G; Malagutti P; Campo G; Ferrari F; Barbieri D; Cicchitelli G; McFadden EP; Merlini F; Ansani L; Guardigli G; Bettini A; Parrinello G; Boersma E; Ferrari R; JAMA; 2005 May; 293(17):2109-17. PubMed ID: 15870414 [TBL] [Abstract][Full Text] [Related]
15. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ; N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304 [TBL] [Abstract][Full Text] [Related]
16. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Topol EJ; Mark DB; Lincoff AM; Cohen E; Burton J; Kleiman N; Talley D; Sapp S; Booth J; Cabot CF; Anderson KM; Califf RM Lancet; 1999 Dec; 354(9195):2019-24. PubMed ID: 10636365 [TBL] [Abstract][Full Text] [Related]
17. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Kleiman NS; Lincoff AM; Kereiakes DJ; Miller DP; Aguirre FV; Anderson KM; Weisman HF; Califf RM; Topol EJ Circulation; 1998 May; 97(19):1912-20. PubMed ID: 9609084 [TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial. Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748 [TBL] [Abstract][Full Text] [Related]
19. Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial. Lincoff AM Am Heart J; 2000 Feb; 139(2 Pt 2):S46-52. PubMed ID: 10650316 [No Abstract] [Full Text] [Related]
20. Will blocking the platelet save the diabetic? King SB; Mahmud E Circulation; 1999 Dec 21-28; 100(25):2466-8. PubMed ID: 10604881 [No Abstract] [Full Text] [Related] [Next] [New Search]